ACEI/ARB significantly attenuated cardiac dysfunction caused by anthracycline-based chemotherapy and/or trastuzumab in early-stage breast cancer patients.
Does ACEI/ARB prevent cardiotoxicity in early-stage breast cancer patients receiving anthracycline-based chemotherapy and/or trastuzumab?
ACEI/ARB may serve as effective cardioprotective agents to attenuate cardiac dysfunction in early-stage breast cancer patients undergoing cardiotoxic chemotherapy.
Absolute Event Rate: 0% vs 0%
Our study suggests that ACEI/ARB significantly attenuate the cardiac dysfunction caused by anthracycline-based chemotherapy and/or trastuzumab. Further studies are required to confirm the effectiveness of this cardioprotective agent.
Dong et al. (Sun,) reported a other. ACEI/ARB significantly attenuated cardiac dysfunction caused by anthracycline-based chemotherapy and/or trastuzumab in early-stage breast cancer patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: